Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | PRKDC | P78527 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13351443 | 0.85 | ALDH1A1 (0.51) | CYP3A4ALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL6518325 | 0.84 | MEN1 (0.48) | ALDH1A1MAPTPOLBNPC1RAB9A | |
| SCHEMBL6514760 | 0.84 | MEN1 (0.48) | ALDH1A1MAPTPOLBNPC1RAB9A | |
| SCHEMBL13319121 | 0.83 | ALDH1A1 (0.49) | CYP3A4ALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL12436736 | 0.82 | ALDH1A1 (0.54) | CYP3A4ALDH1A1MAPTKDM4EALOX15 | |
| Ammonia Solution, Strong SCHEMBL27817247 | 0.80 | ALDH1A1 (0.53) | CYP3A4ALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL2187742 | 0.80 | ALDH1A1 (0.53) | CYP3A4ALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL3914603 | 0.80 | ALDH1A1 (0.54) | CYP3A4ALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL11618422 | 0.79 | ALDH1A1 (0.44) | CYP3A4ALDH1A1MAPTKDM4EALOX15 | |
| SCHEMBL27246203 | 0.79 | POLB (0.48) | CYP3A4ALDH1A1MAPTKDM4EALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288372-B2 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. (US) | 2007-10-30 | — | — | US | claimed |
| US-20030219780-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | AMBERGEN, INC. | 2003-11-27 | — | — | US | claimed |
| US-5744101-A | Photolabile nucleoside protecting groups | AFFYMAX TECHNOLOGIES N.V. (GB) | 1998-04-28 | — | — | US | claimed |
| WO-1993022680-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF OLIGONUCLEOTIDES AND OTHER BIOLOGICAL POLYMERS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-11-11 | — | — | WO | claimed |
| US-20230193223-A1 | NUCLEOTIDE TRANSIENT BINDING FOR SEQUENCING METHODS | Life Technologies Corporation | 2023-06-22 | — | — | US | disclosed |
| US-11447756-B2 | Nucleotide transient binding for sequencing methods | Life Technologies Corporation (US) | 2022-09-20 | — | — | US | disclosed |
| US-20200278298-A1 | SYSTEMS AND METHODS FOR GENETIC SEQUENCING | Life Technologies Corporation | 2020-09-03 | — | — | US | disclosed |
| US-20200231948-A1 | NUCLEOTIDE TRANSIENT BINDING FOR SEQUENCING METHODS | Life Technologies Corporation | 2020-07-23 | — | — | US | disclosed |
| US-10605734-B2 | Systems and methods for genetic sequencing | Life Technologies Corporation (US) | 2020-03-31 | — | — | US | disclosed |
| US-10597642-B2 | Nucleotide transient binding for sequencing methods | Life Technologies Corporation (US) | 2020-03-24 | — | — | US | disclosed |
| US-20190255503-A1 | SILANE MIXTURES | AFFYMETRIX, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10336991-B2 | Mutant RB69 DNA polymerase | Life Technologies Corporation (US) | 2019-07-02 | — | — | US | disclosed |
| US-5412087-A | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces | AFFYMAX TECHNOLOGIES N.V. (AN) | 1995-05-02 | — | — | US | disclosed |
| EP-0562025-A4 | — | — | 1994-03-30 | — | — | EP | disclosed |
| WO-1993022680-A1 | SPATIALLY-ADDRESSABLE IMMOBILIZATION OF OLIGONUCLEOTIDES AND OTHER BIOLOGICAL POLYMERS ON SURFACES | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-11-11 | — | — | WO | disclosed |
| EP-0562025-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1993-09-29 | — | — | EP | disclosed |
| WO-1992010092-A1 | VERY LARGE SCALE IMMOBILIZED POLYMER SYNTHESIS | AFFYMAX TECHNOLOGIES N.V. (AN) | 1992-06-25 | — | — | WO | disclosed |
| US-4115566-A | 7α Ureido cephem-4-carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
| US-3996208-A | PENICILLINS | CIBA-GEIGY CORPORATION (US) | 1976-12-07 | — | — | US | disclosed |
| US-3954802-A | Substituted-ureido derivatives of penam 3-carboxylic acid and cephem 4-carboxylic acid | CIBA-GEIGY CORPORATION (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030219780-A1 | Methods for the preparation of chemically misaminoacylated tRNA via protective groups | NSUN3, TRMT1, TARBP1 | CYP3A4 4108/4885ALDH1A1 3495/4885MAPT 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.